Raquel Yokoda, Bolni M Nagalo, Brent Vernon, Rahmi Oklu, Hassan Albadawi, Thomas T DeLeon, Yumei Zhou, Jan B Egan, Dan G Duda, Mitesh J Borad
With the advancement of a growing number of oncolytic viruses (OVs) to clinical development, drug delivery is becoming an important barrier to overcome for optimal therapeutic benefits. Host immunity, tumor microenvironment and abnormal vascularity contribute to inefficient vector delivery. A number of novel approaches for enhanced OV delivery are under evaluation, including use of nanoparticles, immunomodulatory agents and complex viral-particle ligands along with manipulations of the tumor microenvironment...
2017: Oncolytic Virotherapy